JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 30, 2007; DOI: 10.1124/jpet.106.116426


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.116426v1
322/2/610    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sakamoto, S.
Right arrow Articles by Sugiyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakamoto, S.
Right arrow Articles by Sugiyama, Y.


Received for publication October 31, 2006.
Revised April 26, 2007.
Accepted for publication April 26, 2007.

Glucuronidation Converting S-8921 to a Potent ASBT Inhibitor, resulting in a Hypocholesterolemic Action

Shingo Sakamoto 1, Hiroyuki Kusuhara 2, Kenji Miyata 1, Hiroyuki Shimaoka 1, Takushi Kanazu 1, Yumiko Matsuo 1, Kohji Nomura 1, Noboru Okamura 3, Seijiro Hara 1, Kazutoshi Horie 1, Takahiko Baba 4, Yuichi Sugiyama 2*

1 Shionogi & Co., Ltd. 2 The University of Tokyo 3 Kobe University Graduate School of Medicine 4 Shionogi & Co.

* Address correspondence to: E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp

Abstract

S-8921 is a novel inhibitor of the ileal apical sodium-dependent bile acid transporter (ASBT/SLC10A2) developed for the treatment of hypercholesterolemia. The present study investigated the hypocholesterolemic action of S-8921 glucuronide (S-8921G) in rats. The plasma concentration of S-8921G was higher than that of S-8921 after single oral administration of S-8921 in normal rats, and S-8921G was excreted into the bile (13% of dose). Oral administration of either S-8921 or S-8921G reduced the serum total cholesterol, particularly non-high density lipoprotein cholesterol, in hypercholesterolemic normal rats. In Gunn rats devoid of UGT1A activity, S-8921G was undetectable both in the plasma and bile specimens, and only S-8921G administration significantly reduced the serum non-high density lipoprotein cholesterol. An in vitro inhibition study showed that glucuronidation converts S-8921 to a 6,000-fold more potent inhibitor of hASBT (Ki 18 nM versus 109 µM). S-8921G was detected both in the portal plasma and loop when S-8921 was administered into the loop of the rat jejunum although the cumulative amount of S-8921G recovered in the bile was 5-fold greater than that in the loop. The uptake of S-8921G by freshly prepared rat hepatocytes was saturable, and sodium-dependent and -independent systems were involved. Organic anions, such as bromosulfophthalein, estrone 3-sulfate and taurocholic acid, inhibited the uptake. These results suggest that UDP-glucuronosyltransferase-1 isoforms play a critical role in the hypocholesterolemic action of S-8921 by converting S-8921 to a more potent ASBT inhibitor, and organic anion transporter(s) are also involved in its pharmacological action through the biliary excretion of S-8921G.


Key words: ASBT, Gunn rats, UGT1, glucuronidation, hypocholesterolemic action, transport





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.